Intellia Therapeutics, Inc.
Intellia Therapeutics is a biopharmaceutical company developing treatments for severe diseases using CRISPR gene editing, oligonucleotides, lipid nanoparticles and other technologies. Its lead investigational candidates are lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for transthyretin amyloidosis. Both are in Phase 3 development. Intellia also advances earlier-stage programs independently and with collaborators, including work on gene editing beyond the liver and allogeneic CAR-T cell therapies. Intellia’s business includes developing its own product candidates and collaborating with partners on research, development and commercialization. Collaboration arrangements can provide upfront payments, milestone payments, royalties and cost sharing. The company also licenses its CRISPR technologies to partners for therapeutic development. Intellia is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Intellia Therapeutics (NTLA) awarded 12,900 RSUs to three new employees as inducement grants. The RSUs vest over three years and were approved under the company's 2024 Inducement Plan, per Nasdaq Rule 5635(c)(4).
Intellia Therapeutics (NTLA) reported Q3 EPS of -$0.91, missing estimates by $0.11, and revenue of $7.16M, below the $10.23M consensus. The stock is up 3.1% over 3 months but down 0.08% year-over-year. Analysts have mixed EPS revisions, and InvestingPro rates its financial health as 'fair performance.'
Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning NTLA (Intellia Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 3 bearish.
Recent NTLA coverage spans earnings, regulation and financial news.
In the last 30 days, NTLA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($108K). The most active reporter was LEONARD JOHN M, President and CEO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The small equity grant is unlikely to move the stock materially.
Earnings miss likely triggers sell pressure.
The earnings release shows higher cash but widening net loss and lower collaboration revenue, suggesting near‑term pressure on the stock.
Earnings preview suggests potential volatility; a miss could pressure the stock, while a beat may trigger upside.
Enrollment completion signals progress toward pivotal data, likely supporting the stock.
AlphAI scores every news story that mentions NTLA with an AI model for sentiment and relevance, and aggregates insider trades from Intellia Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Intellia Therapeutics (NTLA) awarded 12,900 RSUs to three new employees as inducement grants. The RSUs vest over three years and were approved under the company's 2024 Inducement Plan, per Nasdaq Rule 5635(c)(4).
Intellia Therapeutics (NTLA) reported Q3 EPS of -$0.91, missing estimates by $0.11, and revenue of $7.16M, below the $10.23M consensus. The stock is up 3.1% over 3 months but down 0.08% year-over-year. Analysts have mixed EPS revisions, and InvestingPro rates its financial health as 'fair performance.'
Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ
Intellia Therapeutics (NTLA) is set to report Q3 results, with analysts expecting a loss of $0.80 per share and revenue of $10.2M, a 33% sequential improvement. The company faces investor scrutiny after a disappointing Q2 and operates in the competitive CRISPR gene-editing sector. Key focus areas include revenue consistency, pipeline progress, and cash runway. Analysts are divided, with a mean price target of $23.11, implying 95% upside from the current share price.
Intellia Therapeutics (NASDAQ:NTLA) completed enrollment in the MAGNITUDE-2 phase 3 trial for nex-z, a CRISPR-based therapy for ATTRv-PN. The trial involves 60 patients and evaluates efficacy and safety over 18 months. Nex-z is also being tested in a separate phase 3 trial for ATTR-CM and has received Orphan Drug and RMAT designations. Intellia collaborates with Regeneron on its development.
Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.
The FDA issued draft guidance to accelerate personalized gene therapies for rare diseases, offering regulatory clarity for developers. The move aims to streamline approval processes for tailored treatments, benefiting companies like Ultragenyx Pharmaceutical (RARE).
Intellia Therapeutics (NTLA) will host an investor webcast on Nov. 12 to discuss ACAAI presentations and lonvo-z commercialization plans. Lonvo-z, under FDA Priority Review, has a PDUFA target date of Mar. 10, 2027. Presentations will include four-year follow-up data and patient perspectives on lonvo-z treatment for hereditary angioedema (HAE).
Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.
Intellia Therapeutics (NTLA) appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings extensive experience in rare disease therapies and will lead clinical development and regulatory affairs. The company is advancing its CRISPR gene editing pipeline, including Phase 3 trials for transthyretin amyloidosis.
